Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 versus T-DM1 plus short induction docetaxel in first-line HER2-positive advanced breast cancer
2014-000793-19Phase 2Active
- Sponsor
- SOLTI
- Start
- Aug 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Trastuzumab emtansine monotherapy with Trastuzumab emtansine plus short induction docetaxel (2 arms). Primary endpoint: Progression-free survival rate at 4 months. Started Aug 2014; status: active.
02
Drugs
trastuzumab emtansinedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000793-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000793-19.